A series of 1-(6-aminopurin-9-yl)-1-deoxy-N-methyl--D-ribofuranuronamides characterised by 2-dialkylamino-7-methyloxazolo [4,5-b]pyridin-5-ylmethyl substituents on N6 of interest for screening as selective adenosine A3 receptor agonists, have been synthesised. This work involved the synthesis of 2-dialkylamino-5-aminomethyl-7-methyloxazolo [4,5-b]pyridines and analogues that were coupled with the known 1-(6-chloropurin-9-yl)-1-deoxy-N-methyl--D-ribofuranuronamide. The oxazolo [4,5-b]pyridines were synthesized by regioselective functionalisation of 2,4-dimethylpyridine N-oxides. The regioselectivities of these reactions were found to depend upon the nature of the heterocycle with 2-dimethylamino-5,7-dimethyloxazolo [4,5-b]pyridine-N-oxide undergoing regioselective functionalisation at the 7-methyl group on reaction with trifluoroacetic anhydride in contrast to the reaction of 4,6-dimethyl-3-hydroxypyridine-N-oxide with acetic anhydride that resulted in functionalisation of the 6-methyl group. To optimise selectivity for the A3 receptor, 5-aminomethyl-7-bromo-2-dimethylamino-4-[(3-methylisoxazol-5-yl)methoxy]benzo [d]oxazole was synthesised and coupled with the 1-(6-chloropurin-9-yl)-1-deoxy-Nmethyl--D-ribofuranuronamide. The products were found to act as adenosine A3 agonists but further work is required to optimise potency and selectivity.
Introduction
The G-protein-coupled adenosine receptors are important in regulating a wide range of physiological functions. Specifically A3 receptor agonists have been identified as being of interest for the treatment of cardiac ischaemia 1 and many compounds have been evaluated for selective A3 receptor agonist activity. 2 Indeed, N6 substituted derivatives of adenosine and analogues have been found to exhibit useful A3 agonist activity, the N6-(iodobenzyl)purinylribofuranuronamide 1 3a being an early example, see Figure 1 , with many more homologues subsequently synthesized and evaluated. 2, 4 In particular, the N6-(benzoxazolylmethyl)purinyluronamide 2 was identified as a promising lead. 5 However, concerns about toxicity issues due to the iodine substituent and the possible improvement in selectivity following incorporation of an oxazolopyridine rather than a benzoxazole into the N6 substituent, led to the selection of the ribofuranuronamide 3 as the next target for synthesis, 6 see Figure 2 . We here report a synthesis of this compound and several of its homologues together with the results of preliminary biological evaluation of these compounds. 
Results and discussion

Synthesis of oxazolopyridine derived adenosine derivatives
Following well established literature precedent, 2-4 the uronamide 3 was to be prepared from the 2-dimethylamino-5-aminomethyl-7-methyloxazolo[4, 5-b] pyridine 5 and the known 6-chloropurinyluronamide 4, 7 the challenge in the work being to develop a synthesis of the oxazolopyridine 5. Initially it was intended to prepare this oxazolopyridine from 5,7-dimethyl-2-dimethylamino-oxazolopyridine 6 by rearrangement of the corresponding pyridine N-oxide. In turn the oxazolopyridine 6 was to be prepared from 5-hydroxy-6-nitro-2,4-lutidine (7) that it was intended to prepare from 2,4-lutidine (8), see Figure 3 .
Figure 3 Planned synthesis of the target compound 3
Nitration of 2,4-lutidine (8) using potassium nitrate in fuming sulfuric acid gave a mixture of 5-nitro-2,4-lutidine (9) and its 3-nitro isomer from which the required isomer 9 was isolated by fractional distillation albeit in only a low yield. 8a Hydrogenation gave the 5-amino-2,4-lutidine (10) that was converted into the 5-hydroxy-2,4-lutidine (11) by diazotisation using sodium nitrite in aqueous sulfuric acid. In this reaction it was important to use just a small excess of sulfuric acid to avoid the formation of the pyrazolopyridine 12. 9 Nitration of the hydroxylutidine 11 using concentrated nitric and sulfuric acids 10 led to decomposition but the use of ceric ammonium nitrate and sodium bicarbonate in acetonitrile heated under reflux 11 gave the required 5-hydroxy-6-nitro-2,4-lutidine (7) in a modest but reproducible yield. Hydrogenation of the nitrolutidine 7 gave the corresponding hydroxyaminolutidine 13 that was converted into the 2-dimethylamino-oxazolopyridine 6 using dichloromethylene-(dimethyl)ammonium chloride, see Scheme 1. Oxidation of the oxazolopyridine 6 using meta-chloroperoxybenzoic acid gave the N-oxide 14, an X-ray crystal structure confirming that the product was the pyridine N-oxide shown, see Figure 4 . When this N-oxide was reacted with an excess of acetic anhydride, standard conditions for effecting regioselective hydroxylation of a methyl group ortho to an N-oxide, 8 ,12 a mixture of several products was obtained. However, the use of trifluoroacetic anhydride in dichloromethane under reflux, 13 followed by saponification, gave a single product 15 in which the methyl group remote from the Noxide had been hydroxylated, albeit in only a modest yield, see Scheme 1.
The regioselectivity of this hydroxylation was initially indicated by the 1 H- 15 N gHMBC NMR spectrum that showed a three-bond coupling of 5.0 Hz between the remaining aryl methyl group at 1.5 and the pyridine nitrogen in contrast to the small coupling of 0.5 Hz between the aryl methylene protons at  5.0 and the pyridine nitrogen. This structural assignment was eventually confirmed by Xray diffraction, see Figure 5 . The selective formation of the 7-hydroxymethyloxazolopyridine 15 rather than its 5-hydroxymethyl isomer was unexpected since typically an ortho methyl group is hydroxylated on treatment of a pyridine N-oxide with an acyl anhydride. 8 This meant that it was necessary to hydroxylate the ortho methyl group before assembling the oxazolopyridine.
In our hands, oxidation of the 5-hydroxy-2,4-lutidine 11 to its Noxide 16 was carried out using meta-chloroperoxybenzoic acid. The conversion of the N-oxide 16 into the bis-acetate 17 using acetic anhydride is known and proceded without incident, the structure of the product being assigned according to the literature. 8 Selective deacetylation of the aromatic hydroxyl group was carried out using pyrrolidine in DCM, 14 as sodium hydroxide was less selective and gave a mixture of products, and nitration of the resulting hydroxypyridine 18 to the nitropyridine 19 was best achieved using ceric ammonium nitrate as before. Attempts to reduce the nitropyridine 19 to the corresponding aminopyridine by hydrogenation were complicated by hydrogenolysis of the acetoxy group. To convert the acetoxy group into a less good leaving group, it was saponified to give the alcohol 20 and hydrogenation of this now proceeded uneventfully to give 2-amino-3-hydroxy-6-hydroxymethyl-4-methylpyridine (21) . However, it transpired that this compound was relatively insoluble in many organic solvents and correspondingly difficult to functionalise. The dihydroxynitropyridine 20 was therefore converted into its monotert-butyldiphenylsilyl ether 22. Hydrogenation of this gave the aminopyridine 23 that on treatment with dichloromethylene(dimethyl)ammonium chloride gave the required oxazolopyridine 24. Desilylation provided the 5-hydroxymethyl-7-methyloxazolo[4,5-b]pyridine 25, see Scheme 2.
The structures of the products in Scheme 2 were assigned on the basis of the literature precedent for the pyridine N-oxide reaction 8 and from spectroscopic data. The 5-hydroxymethyl-7-methyloxazolopyridine 25 was distinctly different from its 7-hydroxmethyl-5-methyl isomer 15 prepared earlier.
To complete the synthesis of the uronamide 3, the hydroxymethyloxazolopyridine 25 had to be converted into its aminomethyl homologue 5. This was achieved using a Mitsunobu reaction 15 of the alcohol 25 with 2-nitrobenzene sulfonamide to prepare the N-alkylsulfonamide 26. This reaction was complicated by bis-alkylation of the 2-nitrobenzene sulfonamide but was not optimised at this stage. Desulfonylation gave the primary amine 5 and coupling this with the 6-chloropurine 4 gave the N6-substituted purinyluronamide 27. Selective hydrolysis of this acetonide 27 gave the required ribofuranuronamide 3, see Scheme 3.
The products in Scheme 3 were identified on the basis of their spectrocopic data. Following evaluation of the uronamide 3 for biological activity, vide infra, it was decided to prepare homologues for further studies. The next compound identified for synthesis was the diethylamino analogue 37, see Scheme 4. This required the synthesis of the 2-diethylamino-5-aminomethyl-7-methyloxazolo[4,5-b]pyridine 35. As dichloromethylene(diethyl)ammonium chloride was not commercially available at the time, the original synthesis had to be modified. Therefore, following the literature precedent, the aminophenol 23 was converted into the thione 28 using carbon disulfide and potassium hydroxide in ethanol, 16 the product being identified as the thione tautomer by analogy with the literature. 17 The ARTICLE attempted direct conversion of the thione 28 into the corresponding diethylamino-oxazole using diethylamine delivered unchanged starting material, perhaps because of the volatility of diethylamine. The thione was therefore converted into the 2-chloro-oxazole 29 using thionyl chloride. Displacement of chloride using diethylamine gave the required 2-diethylamino-oxazole 30 17 that was desilylated to give the alcohol 31. To avoid the bis-alkylation side-reaction observed during the synthesis of the amine 5, the Mitsunobu reaction of the alcohol 31 was carried out using the N-Boc-protected 2-nitrobenzene sulfonamide 32. 18 A good yield of the alkylated sulfonamide 33 was obtained and, following removal of the Bocgroup, denosylation of the resulting sulfonamide 34 19 gave the required primary amine 35, see Scheme 4.
The primary amine 35 was coupled with the 6-chloropurine 4 as before to obtain the N6-substituted purinyluronamide 36 and this was deprotected to give the target uronamide 37, see Scheme 4. The structures of the products in Scheme 4 were assigned using spectroscopic data.
Scheme 4 Synthesis of the diethylamino substituted adenosine uronamide 37 Reagents and conditions (i) CS2, KOH, EtOH, reflux, 3 h (83%); (ii) SOCl2, Na2CO3, benzene, 50 o C, 3 h; (iii) Et2NH, benzene, rt, 1 h (70% from 28); (iv) TBAF, THF, rt, 1 h (93%); (v) Ph3P, THF, DIAD, rt, 16 h (98%); (vi) TFA, rt, 1 h (79%); (vii) PhSH, K2CO3, MeCN, rt, 16 h (85%); (viii) 4, Et3N, EtOH, reflux, 16 h (55%); (ix) aq. HCl, 65 o C, 1 h (46%).
At this point it was decided to investigate the effect of a methyl substituent on the methylene group attached to N6. This introduces a new stereogenic centre but initially mixtures of epimers were prepared for studies of their biological activity although the synthesis that was developed could be modified to control the chirality at this position if required, see Scheme 5.
Oxidation of the alcohols 25 and 31 gave the corresponding aldehydes 38 and 39. Reaction of these with racemic tertbutanesulfinamide gave the racemic sulfinimides 40 and 41. 20 The reaction of these with methylmagnesium bromide was stereoselective and gave, in each case, essentially a single, albeit racemic, adduct 42 and 43. The relative configurations of the two stereogenic centres were assigned by analogy with the literature. 21 Methanolysis gave the racemic amines 44 and 45 and these were coupled with the 6-chloropurine 4 to give mixtures of the epimeric purinyluronamides 46 and 47. A small amount of kinetic resolution was observed in these reactions as the products were found to correspond to 60 : 40 mixtures of the two diastereoisomers. Finally deprotection gave the target compounds 48 and 49. Again mixtures of epimers were obtained but as the Grignard addition reactions had been highly diastereoselective, the use of enantiomerically enriched tert-butanesulfinamide would have delivered one or other of the epimers selectively. The structures shown were assigned to the products in Scheme 5 using spectroscopic data. 
Synthesis of an N6-benzoxazolylmethylpurinyluronamide
Although the biological activities of the uronamides 3, 36, 48 and 49 were promising, it was decided that further structural changes in the N6 substituent were required to achieve the required biological activity and selectivity. The (N6-benzoxazolylmethylpurinyl)-uronamide 50 was selected as the next synthetic target, see 
ARTICLE
This is analogous to the known agonist 2 but with a bromine substituent rather than the labile iodide and an extra hetarylmethoxy substituent to facilitate selective binding.
Figure 4
The strategy for the synthesis of the (N6-benzoxazolylpurinyl)uronamide 50
As before it was the synthesis of the heavily substituted benzoxazole 51 that constituted the challenge in preparing uronamide 50. Embedded within the benzoxazole is a pentasubstituted benzene ring. It was decided to use 2-nitroresorcinol (52) as the starting material for this synthesis, see Figure 4 . The conversion of this resorcinol into the benzoxazole 51 would require introduction of the bromine and aminomethyl substituents and discrimination between the two hydroxyls so that one could be incorporated into the oxazole and the other one alkylated.
Initial studies involved the known 22 carboxymethylation of the protected aminoresorcinol 53 that was readily available from 2-nitroresorcinol in three steps. However in our hands only complex mixtures of products were obtained using n-butyllithium and either Mander's reagent 23 or methyl chloroformate as the electrophile, see Scheme 6.
Scheme 6
Unsuccessful carboxymethylation of the protected resorcinol 53.
Carboxymethylation of the bis-MOM-protected iodonitroresorcinol 56 using phenylmagnesium bromide to effect halogen-metal exchange followed by reaction of the organometallic intermediate with Mander's reagent is reported to give the regioselectively monodeprotected ester 57, see Scheme 7. 24 The starting material 56 for this conversion is available in two steps from 2-nitroresorcinol 52. 24 However, in our hands the reported procedure for the conversion of the iodide 56 into the ester 57 gave a complex mixture of products. Attempts to effect this conversion using different electrophiles were similarly unsuccessful. However, studies into palladium(0) catalysed methoxycarbonylation procedures were more successful. 25, 26 The optimum catalyst system was palladium(II) acetate and the hindered electron-rich 2,3,5,7-tetramethyl-2,4,8-trioxa-6-phenyl-6-phospha-adamantane 65 with methanol as the solvent rather than a methanol -N,N-dimethylformamide mixed solvent system, and gave an excellent yield of the mono-deprotected ester 57 after 12 h at 80 o C, see Scheme 7.
The regioselectivity of the monodeprotection was not confirmed at this stage but the product had NMR data identical to those reported in the literature for isomer 57. 24 Bromination of ester 57 was regioselective as would be expected but was accompanied by loss of the remaining MOM-ether and gave the resorcinol 58. This was slighly disappointing since it meant that discrimination between the two hydroxyl groups had to be carried out. Nevertheless the synthesis was continued in that reduction of the nitro group was achieved using zinc and acetic acid in methanol, conditions known to be compatible with both phenolic and ester groups, to give the aminoresorcinol 59.
At this point it was decided to investigate the introduction of the oxazole since it was hoped that hydrogen bonding between the ester and the ortho phenolic hydroxyl group would reduce its reactivity relative to the hydroxyl group that was para to the carboxymethyl substituent. In the event, reaction with dichloromethylene-(dimethyl)ammonium chloride gave a single product that was provisionally identified as the required isomer 60. This structural assignment was confirmed later in the synthesis.
With the assumption that the oxazole was the required regioisomer 60, the free hydroxyl group was alkylated using 5-hydroxymethyl-3-methylisoxazole under Mitsunobu conditions to provide 61. Reduction of the ester 61 using lithium aluminium hydride was accompanied by debromination but calcium borohydride 27 was both sufficiently reactive and selective and gave the alcohol 62 in a good yield. Long-range correlation in the 1 H NMR spectrum of the alcohol 62 between the two benzylic methylene groups were consistent with the required ortho-orientation of the hydroxymethyl and alkoxy side chains and the structure of the alcohol 62 was finally confirmed by X-ray diffraction, see Figure 5 . Figure 5 The structure of the alcohol 62 as confirmed by X-ray diffraction
The alcohol 62 was converted into the required primary amine 51 by a Mitsunobu reaction using 2-nitrobenzene sulfonamide, monoalkylation being the major reaction pathway in this hindered system. Denosylation of the intermediate sulfonamide 63 then gave the primary amine 51. Substitution of the chloride from the 6-chloropurine 4 using the amine 51 proceded uneventfully, and deprotection of the resulting acetonide 64 gave the required N6-substituted purinyluronamide 50.
This potentially selective adenosine A3 receptor agonist 50 had been prepared in twelve steps from the commercially available resorcinol 62 in an overall yield of 21%. The structures of the products shown in Scheme 7 were consistent with their spectroscopic data, the structures of the benzoxazoles being confirmed by the X-ray crystal structure of the alcohol 62.
Compounds 3, 36, 48, 49 and 50, were screened for activity as adenosine A3 receptor agonists and were found to demonstrate useful activity.
Of interest in the synthetic work described here is the unexpected regioselectivity of the redox reaction of the pyridine Noxide 14 since usually an ortho-methyl substituent is oxidised in 2,4-dimethylpyridines, 12 as was observed for the analogous reaction of the 5-hydroxy-2,4-dimethylpyridine N-oxide 16. The origin of this unexpected regioselectivity in the reaction of pyridine N-oxide 14 is not obvious, but must involve the selective deprotonation of the 7-methyl group to give the p-quinoidal intermediate 66 that reacts with trifluoroacetate via an intermolecular process, see Figure 6 . Hydrolysis of the resulting product 67 could then deliver the observed product 15. The oxazole ring clearly has a role in influencing this regioselectivity and may well be protonated or trifluoroacetylated under the reaction conditions. The enhanced acidity of the p-methyl group may then be due to an electrostatic effect involving the proximate oxazole ring.
Figure 6
Intermediates that may be involved with the regioselective redox reaction of pyridine N-oxide 14
Other aspects of the syntheses that may be of some interest are the mild conditions used for the nitration of the hydroxypyridines 11 and 18; the improved conditions of the conversion of iodide 56 into the ester 57, and the acccompanying regioselective monodeprotection; the regioselective formation of the benzoxazole 60; and the overall strategies used in the synthesis of the highly substituted pyridine and benzene derivatives used in this work. Further studies leading to the additional development of these adenosine A3 receptor agonists would be of interest.
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Experimental
General experimental details
1 H and 13 C NMR spectra were recorded on Varian Unity Inova 400 and Varian Unity Inova 300 spectrometers with residual nondeuterated solvent as the internal standard. Only distinguishable peaks are reported for minor isomers in isomeric mixtures. IR spectra were recorded on an ATI Mattson Genesis FTIR as thin films produced by evaporation of a dichloromethane solution on sodium chloride plates unless otherwise stated. Mass spectra were recorded on Fison VG Trio 2000 and Kratos Concept spectrometers. Chromatography refers to flash column chromatography using Merck silica gel 60 H (230-300 mesh). Tetrahydrofuran (THF) was dried and distilled from sodium metal using benzophenone as an indicator under an atmosphere of nitrogen. Dichloromethane was dried and distilled from calcium hydride under an atmosphere of nitrogen. Ether refers to diethyl ether, which was dried and distilled from sodium metal using benzophenone as an indicator under an atmosphere of nitrogen. Light petroleum refers to the fraction of petroleum ether distilled between 40-60 C. Benzene and hexane were dried over sodium metal. Butyllithium (1.6 M in hexanes) was titrated against a solution of propan-2-ol in xylene with 2,2-bipyridine as an indicator. Triethylamine and di-isopropylamine were dried over potassium hydroxide pellets. Brine refers to saturated aqueous sodium chloride.
4,6-Dimethyl-3-hydroxy-2-nitropyridine (7)
Fuming sulfuric acid (147 g, 1.498 mol) was added slowly with stirring to 2,4-lutidine (8) (15 g, 140 mmol) cooled in an ice bath. Potassium nitrate (25.5 g, 252 mmol, 1.8 eq) was added slowly, and the reaction mixture gradually heated to 100 °C and maintained at this temperature for 8 h. The reaction mixture was then heated at 120 °C for 8 h. After cooling to rt, the reaction mixture was poured onto ice (300 g), then neutralized to pH 7 using K2CO3 and filtered. The filtrate was extracted with chloroform (5  300 mL) and the organic extracts were dried (Na2SO4) then concentrated under reduced pressure and the residue distilled to give 5-nitro-2,4-lutidine (9) 8a as a pale oil (3.62 g, 17%), b. Palladium on charcoal (10%, 280 mg, 2 mol%) was added to 5-nitro-2,4-lutidine (9) (2 g, 13.1 mmol) in methanol (39 mL). The mixture was stirred at rt under hydrogen at atmospheric pressure for 16 h then filtered, and concentrated under reduced pressure to leave 5-amino-2,4-lutidine (10) 8a (1.67 g, ca. 100%) used without purification, Rf 0. 13 Sodium nitrite (1.47 g, 21.3 mmol, 1.1 eq) in water (15 mL) was added over a period of 7 min to 5-amino-2,4-lutidine (10) (2.37 g, 19.4 mmol) in aqueous sulfuric acid (4.8%, 37.8 mL) cooled to 0 °C using dry ice/acetone bath. The solution was maintained at 0 °C for 15 min and then heated under reflux for 5 min. After cooling to room temperature, the solution was neutralised to pH 7 with K2CO3 and the mixture extracted with methanol in dichloromethane (10%, 10  100 mL). The organic extracts were dried (Na2SO4) and concentrated under reduced pressure. Chromatography of the residue (50% to 90% Et2O/light petroleum) gave 5-hydroxy-2,4-lutidine (11) 8a as a white solid (1.13 g, 47%), m. 24 mmol, 2.0 eq) was added to 5-hydroxy-2,4-lutidine (11) (1.00 g, 8.12 mmol) and NaHCO3 (2.05 g, 24.36 mmol, 3.0 eq) in anhydrous acetonitrile (93 mL) at rt. The mixture was heated under reflux for 6 h then filtered and the filtrate concentrated under reduced pressure. The residue was taken up into water (30 mL) and extracted with dichloromethane (3  30 mL). The organic extracts were dried (Na2SO4), and concentrated under reduced pressure. Chromatography of the residue (10% to 30% Et2O/light petroleum) gave the title compound 7 as yellow solid (577 mg, 42%), Rf 0.63 (Et2O) (6) A mixture of the nitropyridine 7 (768 mg, 4.60 mmol) and palladium on charcoal (10%, 10 mg, 2 mol%) in ethyl acetate (17 mL) was stirred at rt for 16 h under an atmosphere of hydrogen then filtered through a pad of Celite.
5,7-Dimethyl-2-dimethylamino-oxazolo[4,5-b]pyridine
® The filtrate was concentrated under reduced pressure to leave 2-amino-3-hydroxy-4,6-dimethylpyridine 13 (660 mg) used without purification, Rf 0. 15 A solution of 2-amino-3-hydroxy-4,6-dimethylpyridine 13 (685 mg, 4.96 mmol) and dichloromethylene(dimethyl)ammonium chloride (1.29 g, 7.93 mmol, 1.6 eq) in dry dichloromethane (52 mL) was heated under reflux for 5 h. After cooling, the mixture was poured into saturated aqueous sodium bicarbonate (30 mL) and the mixture extracted with dichloromethane (4  30 mL). The organic extracts were washed with brine, dried (MgSO4) and concentrated under reduced pressure to give the title compound 6 as a pale solid (1.05 g) used without purification, Rf 0.38 (10% MeOH/Et2O), m. 
2-Acetoxymethyl-5-hydroxy-4-methyl-6-nitropyridine (19)
Ceric ammonium nitrate (1.55 g, 2.84 mmol, 1.1 eq) was added to 2-acetoxymethyl-5-hydroxy-4-methylpyridine (18) 
6-tert-Butyldiphenylsilyloxymethyl-3-hydroxy-4-methyl-2-nitropyridine (22)
tert-Butyldiphenylsilyl chloride (245 µL, 0.94 mmol, 1.05 eq) was added to the hydroxymethylpyridine 20 (165 mg, 0.90 mmol) and imidazole (305 mg, 4.48 mmol, 5 eq) in N,N-dimethylformamide (3.6 mL) and the mixture was stirred at room temperature for 12 h. Water (20 mL) was added and the mixture was extracted with dichloromethane (6  20 mL). The organic extracts were dried (Na2SO4) and concentrated under reduced pressure. Chromatography of the residue (2% to 10% Et2O/light petroleum) gave the title compound 22 as a yellow solid (285 mg, 75%), Rf 0.63 (Et2O), m. 
1-[6-(2-Dimethylamino-7-methyloxazolo[4,5-b]pyridin-5-ylmethylamino)-9H-purin-9-yl]-2,3-O-isopropylidene-1-deoxy-N-methyl--D-ribofuranuronamide (27)
A solution of 6-chloropurine-2,3-O-isopropylidene-Nmethyluronamide 4 (38 mg, 0.11 mmol), amine 5 (22 mg, 0.11 mmol) and triethylamine (30 µL, 0.21 mmol, 2.0 eq) in ethanol (1.1 mL) was stirred at 80 °C for 16 h then comcentrated under reduced pressure. Chromatography of the residue (20% to 30% MeOH/Et2O/1% Et3N) gave the title compound 27 as a white solid (51 mg, 90%), Rf 0.27 (20% MeOH/Et2O), m. 
1-[6-(2-Dimethylamino-7-methyloxazolo[4,5-b]pyridin-5-ylmethylamino)-9H-purin-9-yl]-1-deoxy-N-methyl--Dribofuranuronamide (3)
A solution of the acetonide 27 (51 mg, 0.10 mmol) in aqueous hydrogen chloride (1 M, 793 µL) was stirred at 65 °C for 1 h. After cooling, saturated aqueous sodium hydrogen carbonate was added until pH 7 and the mixture was concentrated under reduced pressure. Chromatography of the residue (CH2Cl2 to 10% MeOH/CH2Cl2/1% 
5-tert-Butyldiphenylsiloxymethyl-2-diethylamino-7-methyloxazolo[4,5-b]pyridine (30)
Thionyl chloride (12.6 L, 0.15 mmol) was added to a suspension of the thione 28 (50 mg, 0.1 mmol) and sodium carbonate (18 mg, 0.15 mmol) in benzene (0.13 mL) at 0 ºC and the reaction mixture warmed to 50 °C for 3 h then allowed to cool to rt. Diethylamine (66 L, 0.55 mmol) was added dropwise and the reaction mixture stirred at rt for 1 h. The mixture was partitioned between water (10 mL) and Et2O (4  15 mL). The organic extracts were dried (Na2SO4) then concentrated under reduced pressure. Chromatography of the residue (Et2O to10 % MeOH/Et2O) gave the title compound 30 as a pale oil which solidified upon storage (37 mg, 70 %), Rf 0.38 (50 % Et2O/ light petroleum), m. 
2-Diethylamino-5-hydroxymethyl-7-methyloxazolo[4,5-b]pyridine (31)
Tetrabutylammonium fluoride in tetrahydrofuran (1 M, 0.8 mL, 0.77 mmol) was added to the silyl ether 30 (303 mg, 0.64 mmol) in tetrahydrofuran (10.7 mL) and the reaction mixture stirred for 1 h at rt. After concentration under reduced pressure, the residue was partitioned between water (20 mL) and Et2O (4  20 mL 
5-{(RS)-1-[(RS)-tert-Butylsulfinylamino]ethyl}-2-dimethylamino-7-methyloxazolo[4,5-b]pyridine (42)
Methylmagnesium bromide in ether (3 M, 0.51 mL, 1.6 mmol) was added dropwise to the sulfinimine 40 (132 mg, 0.43 mmol) in tetrahydrofuran (4.3 mL) at -78 ºC. The reaction mixture was stirred at -78 °C for 1 h and then saturated aqueous ammonium chloride (5 mL) was added. The mixture was extracted with ethyl acetate (6  5 mL) and the organic extracts were dried (Na2SO4) and concentrated under reduced pressure. (3 H, s, 7-CH3), 2.57 (3 H, narrow m, NHCH3), 3.57 (4 H, m, 2 x  NCH2CH3), 4.61 (1 H, s, 4-H), 5.24 (2 H, m, 2-H and 3-H 
5-{(RS)-1-[(RS)-tert-
1-{6-[(RS
1,3-Dihydroxy-4-iodo-2-nitrobenzene (55)
24
N-Iodosuccinimide (3.16 g, 12.9 mmol) was added slowly to the nitroresorcinol 52 (2.00 g, 12.9 mmol) in trifluoroacetic acid (50 mL, 0.65 mol) at 0 °C and the reaction mixture was stirred at rt for 16 h, then poured onto ice water (30 mL). The mixture was extracted with toluene (3  10 mL) and the organic extracts were washed with saturated sodium bisulphite, dried (MgSO4) and concentrated under reduced pressure to give the title compound 55 (3. Methyl 3-amino-5-bromo-2,4-dihydroxybenzoate (59) Concentrated acetic acid (0.8 mL) and zinc (67 mg, 1.02 mmol) were added sequentially to the nitro compound 58 (50.0 mg, 0.171 mmol) in methanol (3.3 mL) and the resulting mixture was stirred at rt for 2 min. After filtering through a plug of silica, the filtrate was diluted with water (5 mL) and brine (5 mL) then extracted with ethyl acetate (3  10 mL). The organic extracts were washed with saturated aqueous sodium bicarbonate (5 mL) and water (5 mL DMSO-d6) 10.9,  25.3, 37.3, 60.1, 63.2, 72.1, 73.0, 84.6, 87.8, 92.8, 104.6, 120.0 
1-{6-[7-Bromo-2-dimethylamino-4-(3-methylisoxazol-5-ylmethoxy)benz[d]oxazol-5-ylmethylamino]-9H-purin-9-yl}-1-deoxy-N-methyl--D-ribofuranuronamide (50
